--- title: "Rezolute | 8-K: FY2026 Q2 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/275809296.md" datetime: "2026-02-12T21:19:52.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275809296.md) - [en](https://longbridge.com/en/news/275809296.md) - [zh-HK](https://longbridge.com/zh-HK/news/275809296.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275809296.md) | [繁體中文](https://longbridge.com/zh-HK/news/275809296.md) # Rezolute | 8-K: FY2026 Q2 Revenue: USD 0 Revenue: As of FY2026 Q2, the actual value is USD 0. EPS: As of FY2026 Q2, the actual value is USD -0.22, missing the estimate of USD -0.187. EBIT: As of FY2026 Q2, the actual value is USD -24.22 M. #### Cash, Cash Equivalents, and Investments in Marketable Securities Cash, cash equivalents, and investments in marketable securities totaled $132.9 million as of December 31, 2025, decreasing from $167.9 million as of June 30, 2025. #### Research and Development (R&D) Expenses For the three months ended December 31, 2025, R&D expenses were $14,348 thousand, an increase from $12,627 thousand for the same period a year ago, primarily due to increased expenditures in clinical trial activities and higher employee-related expenses, including one-time severance benefits. For the six months ended December 31, 2025, R&D expenses were $27,497 thousand, compared to $25,381 thousand for the same period in the prior year. #### General and Administrative (G&A) Expenses G&A expenses for the three months ended December 31, 2025, were $9,873 thousand, up from $4,453 thousand for the same period a year ago, mainly due to increased professional fees and employee-related expenses, including one-time severance benefits. For the six months ended December 31, 2025, G&A expenses were $16,541 thousand, compared to $8,640 thousand for the same period in the prior year. #### Total Operating Expenses Total operating expenses were $24,221 thousand for the three months ended December 31, 2025, an increase from $17,080 thousand for the same period in the previous year. For the six months ended December 31, 2025, total operating expenses were $44,038 thousand, compared to $34,021 thousand for the same period in the prior year. #### Loss from Operations Loss from operations was -$24,221 thousand for the three months ended December 31, 2025, compared to -$17,080 thousand for the same period a year ago. For the six months ended December 31, 2025, loss from operations was -$44,038 thousand, compared to -$34,021 thousand for the same period in the prior year. #### Non-Operating Income, Net Non-operating income, net, was $1,447 thousand for the three months ended December 31, 2025, compared to $1,350 thousand for the same period a year ago. For the six months ended December 31, 2025, non-operating income, net, was $3,114 thousand, compared to $2,913 thousand for the same period in the prior year. #### Net Loss Rezolute, Inc. reported a net loss of -$22,774 thousand for the three months ended December 31, 2025, an increase from a net loss of -$15,730 thousand for the same period a year ago. For the six months ended December 31, 2025, the net loss was -$40,924 thousand, compared to -$31,108 thousand for the same period in the prior year. #### Cash and Cash Equivalents Cash and cash equivalents decreased to $11,944 thousand as of December 31, 2025, from $94,107 thousand as of June 30, 2025. #### Investments in Marketable Debt Securities Investments in marketable debt securities increased to $120,994 thousand as of December 31, 2025, from $73,751 thousand as of June 30, 2025. #### Working Capital Working capital was $125,577 thousand as of December 31, 2025, down from $159,233 thousand as of June 30, 2025. #### Total Assets Total assets were $138,629 thousand as of December 31, 2025, decreasing from $175,490 thousand as of June 30, 2025. #### Accumulated Deficit The accumulated deficit increased to -$444,780 thousand as of December 31, 2025, from -$403,856 thousand as of June 30, 2025. #### Total Stockholders’ Equity Total stockholders’ equity was $127,998 thousand as of December 31, 2025, compared to $162,127 thousand as of June 30, 2025. #### Outlook/Guidance Rezolute, Inc. plans to meet with the FDA prior to the end of the first quarter under Breakthrough Therapy Designation to determine next steps for its congenital hyperinsulinism program. Topline results for the upLIFT Phase 3 study for tumor hyperinsulinism are expected in the second half of 2026. The company is undertaking extensive analysis of the sunRIZE study results in preparation for its upcoming FDA meeting. ### Related Stocks - [Rezolute, Inc. (RZLT.US)](https://longbridge.com/en/quote/RZLT.US.md) ## Related News & Research - [09:47 ETINVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute (RZLT)](https://longbridge.com/en/news/277955448.md) - [Dear Lucid Motors Stock Fans, Mark Your Calendars for March 12](https://longbridge.com/en/news/278914321.md) - [Dear Adobe Stock Fans, Mark Your Calendars for March 12](https://longbridge.com/en/news/278432006.md) - [UI Boustead REIT to Commence Trading on Singapore Exchange on March 12](https://longbridge.com/en/news/278669130.md) - [Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management](https://longbridge.com/en/news/278907957.md)